Naloxone Dosing and Hospitalization for Nitazene Overdose: A Scoping Review.
Journal of Medical Toxicology · 2025-02-04 · Scoping review
Abstract
INTRODUCTION: Nitazene compounds are high potency, synthetic opioids, recently detected in the United States illicit opioid supply. This is a scoping review to summarize the available body of literature on naloxone and hospitalization reports in response to nitazene compound overdose. METHODS: This review adhered to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) extension for Scoping Reviews. PubMed, ProQuest, and Google Scholar were accessed. Articles were limited to full-text peer-reviewed publications appearing in scholarly journals between January 2018 and December 2024. Total naloxone dose (in mg, primary outcome) and total length of stay (LOS, in hours, secondary outcome) were recorded. RESULTS: Of 109 articles screened, 103 were excluded (44 non-human; 35 no nitazene exposure, 9 no naloxone administered, 9 post-mortem data only, 3 non-overdose, 2 non-English, and 1 full text unavailable), leaving 6 articles included. Data were described on 19 distinct patients with nitazene compound overdose (meto-, isoto-, proto-, and eto-nitazene), all of whom had naloxone data, and 10 of whom had LOS data. Median total naloxone doses were the following: metonitazene 6.00mg; etonitazene 3.06mg; isotonitazene 3.00mg; protonitazene 1mg (p=0.4). Mean hospital LOS were the following: metonitazene 360 hours; etonitazene 122.25 hrs; isotonitazene 32.67 hrs; protonitazene 20 hrs. CONCLUSION: This scoping review reveals a paucity of data on nitazene compound overdoses and identifies a gap in our current opioid crisis response. Most nitazene cases reviewed involved hospitalization, had high naloxone dosing, and relatively long LOS. Differences in naloxone dose and hospital LOS could underscore the unpredictable and potent nature of these substances.
Abstract © the authors or publisher, via PubMed. Reuse and removal
Tags
Antidotes · Naloxone · Poisoning & substance use · Synthetic opioids
Related articles
- Fentanyl harm reduction strategies among Latinx communities in the United States: a scoping review. (Harm Reduct J, 2024)
- Naloxone dosing in the era of ultra-potent opioid overdoses: a systematic review. (CJEM, 2020)
- Emergency Department-Administered Extended-Release Buprenorphine After Fentanyl Overdose Reversed by Emergency Medical Services With Naloxone. (J Emerg Med, 2026)
- Naloxone dosing by non-medical first-responders at opioid overdoses: findings from a qualitative interview study. (Harm Reduct J, 2025)
- Trends and characteristics during 17 years of naloxone distribution and administration through an overdose prevention program in Pittsburgh, Pennsylvania. (PLoS One, 2025)
- High-dose naloxone formulations are not as essential as we thought. (Harm Reduct J, 2024)